RA Capital Healthcare Fund LP
CIK 0001315082 Name as filed on the most recent filing
Filed as RA Capital Healthcare Fund LP (210)· RA Capital Biotech Fund LP (22)
1,052 transaction lines · from 232 filings · filed 2006-12-29 to 2026-08-14 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised. The 40 most recent are shown; the catalog may hold more for this insider.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Septerna, Inc. 2 filings
- ISSUER Artiva Biotherapeutics, Inc. 11 filings
- ISSUER Parabilis Medicines, Inc. 2 filings
- ISSUER Vor Biopharma Inc. 11 filings
- ISSUER Werewolf Therapeutics, Inc. 8 filings
- ISSUER Hemab Therapeutics Holdings, Inc. 5 filings
- ISSUER Adicet Bio, Inc. 1 filings
- ISSUER Mineralys Therapeutics, Inc. 4 filings
- ISSUER Wave Life Sciences Ltd. 6 filings
- ISSUER Bicara Therapeutics Inc. 2 filings
- ISSUER SpyGlass Pharma, Inc. 1 filings
- ISSUER Climb Bio, Inc. 4 filings
- ISSUER Fulcrum Therapeutics, Inc. 6 filings
- ISSUER Sionna Therapeutics, Inc. 4 filings
- ISSUER PepGen Inc. 3 filings
- ISSUER Cidara Therapeutics, Inc. 1 filings
- ISSUER Tyra Biosciences, Inc. 5 filings
- ISSUER Janux Therapeutics, Inc. 4 filings
- ISSUER 89bio, Inc. 10 filings
- ISSUER An2 Therapeutics, Inc. 7 filings
- ISSUER Aerovate Therapeutics, Inc. 2 filings
- ISSUER Boundless Bio, Inc. 1 filings
- ISSUER Nkarta, Inc. 2 filings
- ISSUER ARS Pharmaceuticals, Inc. 3 filings
- ISSUER Lenz Therapeutics, Inc. 1 filings
- ISSUER Solid Biosciences Inc. 2 filings
- ISSUER Acumen Pharmaceuticals, Inc. 2 filings
- ISSUER Black Diamond Therapeutics, Inc. 1 filings
- ISSUER Dice Therapeutics, Inc. 4 filings
- ISSUER Imara Inc. 5 filings
- ISSUER Acrivon Therapeutics, Inc. 1 filings
- ISSUER Kala Pharmaceuticals, Inc. 5 filings
- ISSUER Icosavax, Inc. 2 filings
- ISSUER Cytek Biosciences, Inc. 8 filings
- ISSUER Therapeutics Acquisition Corp. 1 filings
- ISSUER scPharmaceuticals Inc. 4 filings
- ISSUER Phathom Pharmaceuticals, Inc. 3 filings
- ISSUER Satsuma Pharmaceuticals, Inc. 2 filings
- ISSUER Rhythm Pharmaceuticals, Inc. 3 filings
- ISSUER Orchard Therapeutics plc 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-12 |
Werewolf Therapeutics, Inc. HOWL |
S, Open-market sale | 6,719 disposed | 0.64 | 4,300.16 | Form 4, filing 0001231919-26-000485 | |
| 2026-05-11 |
Artiva Biotherapeutics, Inc. ARTV |
P, Open-market purchase | 6,510,416 acquired | 11.52 | 74,999,992.32 | Form 4, filing 0001231919-26-000491 | |
| 2026-05-11 |
Hemab Therapeutics Holdings, Inc. COAG |
P, Open-market purchase | 25,720 acquired | 25.00 | 643,000.00 | Form 4, filing 0001231919-26-000475 | |
| 2026-05-11 |
Hemab Therapeutics Holdings, Inc. COAG |
P, Open-market purchase | 14,149 acquired | 24.47 | 346,226.03 | Form 4, filing 0001231919-26-000475 | |
| 2026-05-11 |
Werewolf Therapeutics, Inc. HOWL |
S, Open-market sale | 81,678 disposed | 0.67 | 54,724.26 | Form 4, filing 0001231919-26-000485 | |
| 2026-05-11 |
Werewolf Therapeutics, Inc. HOWL |
S, Open-market sale | 5,812 disposed | 0.67 | 3,894.04 | Form 4, filing 0001231919-26-000485 | |
| 2026-05-08 |
Hemab Therapeutics Holdings, Inc. COAG |
P, Open-market purchase | 1,483 acquired | 24.98 | 37,045.34 | Form 4, filing 0001231919-26-000475 | |
| 2026-05-08 |
Werewolf Therapeutics, Inc. HOWL |
S, Open-market sale | 351,514 disposed | 0.71 | 249,574.94 | Form 4, filing 0001231919-26-000485 | |
| 2026-05-08 |
Werewolf Therapeutics, Inc. HOWL |
S, Open-market sale | 25,012 disposed | 0.71 | 17,758.52 | Form 4, filing 0001231919-26-000485 | |
| 2026-05-07 |
Hemab Therapeutics Holdings, Inc. COAG |
P, Open-market purchase | 7,921 acquired | 24.34 | 192,797.14 | Form 4, filing 0001231919-26-000475 | |
| 2026-05-07 |
Hemab Therapeutics Holdings, Inc. COAG |
P, Open-market purchase | 1,985 acquired | 24.95 | 49,525.75 | Form 4, filing 0001231919-26-000475 | |
| 2026-05-06 |
Hemab Therapeutics Holdings, Inc. COAG |
P, Open-market purchase | 53,407 acquired | 24.83 | 1,326,095.81 | Form 4, filing 0001231919-26-000457 | |
| 2026-05-06 |
Hemab Therapeutics Holdings, Inc. COAG |
P, Open-market purchase | 14,611 acquired | 23.77 | 347,303.47 | Form 4, filing 0001231919-26-000457 | |
| 2026-05-05 |
Hemab Therapeutics Holdings, Inc. COAG |
P, Open-market purchase | 87,143 acquired | 24.59 | 2,142,846.37 | Form 4, filing 0001231919-26-000457 | |
| 2026-05-05 |
Hemab Therapeutics Holdings, Inc. COAG |
P, Open-market purchase | 10,268 acquired | 25.00 | 256,700.00 | Form 4, filing 0001231919-26-000457 | |
| 2026-05-04 |
Hemab Therapeutics Holdings, Inc. COAG |
P, Open-market purchase | 2,541,250 acquired | 18.00 | 45,742,500.00 | Form 4, filing 0001231919-26-000457 | |
| 2026-05-04 |
Hemab Therapeutics Holdings, Inc. COAG |
P, Open-market purchase | 133,750 acquired | 18.00 | 2,407,500.00 | Form 4, filing 0001231919-26-000457 | |
| 2026-04-22 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 165,150 disposed | 15.77 | 2,604,415.50 | Form 4, filing 0001231919-26-000409 | |
| 2026-04-20 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 171,963 disposed | 15.77 | 2,711,856.51 | Form 4, filing 0001231919-26-000385 | |
| 2026-04-17 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 458,411 disposed | 16.28 | 7,462,931.08 | Form 4, filing 0001231919-26-000385 | |
| 2026-04-15 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 53,644 disposed | 16.01 | 858,840.44 | Form 4, filing 0001231919-26-000355 | |
| 2026-04-14 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 153,735 disposed | 15.97 | 2,455,147.95 | Form 4, filing 0001231919-26-000355 | |
| 2026-04-13 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 530,610 disposed | 16.15 | 8,569,351.50 | Form 4, filing 0001231919-26-000355 | |
| 2026-04-10 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 828 disposed | 15.75 | 13,041.00 | Form 4, filing 0001231919-26-000333 | |
| 2026-04-09 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 135,201 disposed | 16.59 | 2,242,984.59 | Form 4, filing 0001231919-26-000333 | |
| 2026-04-08 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 353,242 disposed | 16.32 | 5,764,909.44 | Form 4, filing 0001231919-26-000333 | |
| 2026-04-08 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 130,862 disposed | 16.91 | 2,212,876.42 | Form 4, filing 0001231919-26-000333 | |
| 2026-04-06 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 537,754 disposed | 16.51 | 8,878,318.54 | Form 4, filing 0001231919-26-000320 | |
| 2026-04-06 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 44,728 disposed | 17.31 | 774,241.68 | Form 4, filing 0001231919-26-000320 | |
| 2026-04-06 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 6,775 disposed | 18.50 | 125,337.50 | Form 4, filing 0001231919-26-000320 | |
| 2026-04-02 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 258,475 disposed | 18.23 | 4,711,999.25 | Form 4, filing 0001231919-26-000320 | |
| 2026-04-02 |
Vor Biopharma Inc. VOR |
S, Open-market sale | 1,525 disposed | 19.06 | 29,066.50 | Form 4, filing 0001231919-26-000320 | |
| 2026-03-30 |
Mineralys Therapeutics, Inc. MLYS |
P, Open-market purchase | 58,300 acquired | 24.16 | 1,408,528.00 | Form 4, filing 0001231919-26-000300 | |
| 2026-03-30 |
Wave Life Sciences Ltd. WVE |
P, Open-market purchase | 971,091 acquired | 6.50 | 6,312,091.50 | Form 4, filing 0001231919-26-000297 | |
| 2026-03-27 |
Mineralys Therapeutics, Inc. MLYS |
P, Open-market purchase | 310,700 acquired | 23.67 | 7,354,269.00 | Form 4, filing 0001231919-26-000300 | |
| 2026-03-27 |
Wave Life Sciences Ltd. WVE |
P, Open-market purchase | 2,495,623 acquired | 6.43 | 16,046,855.89 | Form 4, filing 0001231919-26-000297 | |
| 2026-03-26 |
Wave Life Sciences Ltd. WVE |
P, Open-market purchase | 4,954,558 acquired | 6.06 | 30,024,621.48 | Form 4, filing 0001231919-26-000297 | |
| 2026-03-26 |
Wave Life Sciences Ltd. WVE |
P, Open-market purchase | 351,224 acquired | 6.38 | 2,240,809.12 | Form 4, filing 0001231919-26-000297 | |
| 2026-02-26 |
Bicara Therapeutics Inc. BCAX |
P, Open-market purchase | 300,000 acquired | 16.00 | 4,800,000.00 | Form 4, filing 0001231919-26-000231 | |
| 2026-02-20 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 74,751 acquired | 7.27 | 543,439.77 | Form 4, filing 0001231919-26-000337 | |
| 2026-02-19 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 74,268 acquired | 7.21 | 535,472.28 | Form 4, filing 0001231919-26-000337 | |
| 2026-02-18 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 74,577 acquired | 7.04 | 525,022.08 | Form 4, filing 0001231919-26-000337 | |
| 2026-02-09 |
SpyGlass Pharma, Inc. SGP |
P, Open-market purchase | 3,441,966 acquired | 16.00 | 55,071,456.00 | Form 4, filing 0001231919-26-000135 | |
| 2026-02-09 |
SpyGlass Pharma, Inc. SGP |
P, Open-market purchase | 248,034 acquired | 16.00 | 3,968,544.00 | Form 4, filing 0001231919-26-000135 | |
| 2026-01-05 |
Climb Bio, Inc. CLYM |
P, Open-market purchase | 7,111 acquired | 3.50 | 24,888.50 | Form 4, filing 0001231919-26-000018 | |
| 2025-12-12 |
Climb Bio, Inc. CLYM |
P, Open-market purchase | 101,462 acquired | 2.86 | 290,181.32 | Form 4, filing 0001231919-25-000616 | |
| 2025-12-11 |
Climb Bio, Inc. CLYM |
P, Open-market purchase | 213,099 acquired | 2.18 | 464,555.82 | Form 4, filing 0001231919-25-000616 | |
| 2025-12-08 |
Fulcrum Therapeutics, Inc. FULC |
S, Open-market sale | 2,706,397 disposed | 14.28 | 38,647,349.16 | Form 4, filing 0001231919-25-000596 | |
| 2025-12-08 |
Fulcrum Therapeutics, Inc. FULC |
S, Open-market sale | 1,377,020 disposed | 13.33 | 18,355,676.60 | Form 4, filing 0001231919-25-000596 | |
| 2025-12-08 |
Fulcrum Therapeutics, Inc. FULC |
S, Open-market sale | 91,722 disposed | 14.98 | 1,373,995.56 | Form 4, filing 0001231919-25-000596 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. RA Capital Healthcare Fund LP, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001315082
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6